|NASDAQ: ATHE||Healthcare / Biotechnology / Australia|
|2.67||+0.1400||+5.53%||Vol 2.00K||1Y Perf -68.08%|
|Mar 24th, 2023 15:45 DELAYED|
|- -||- -%|
|Target Price||3.00||Analyst Rating||Moderate Buy 2.00|
|Potential %||12.36||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★★ 70.07|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★+ 42.96|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||2.26||Earnings Rating||—|
|Market Cap||10.75M||Earnings Date||2nd Oct 2020|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|-6 361 360.00|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||19.95K|
|Avg. Monthly Volume||36.55K|
|Avg. Quarterly Volume||70.71K|
Alterity Therapeutics Limited (NASDAQ: ATHE) stock closed at 2.67 per share at the end of the most recent trading day (a 5.53% change compared to the prior day closing price) with a volume of 2.00K shares and market capitalization of 10.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Alterity Therapeutics Limited CEO is David A. Stamler.
The one-year performance of Alterity Therapeutics Limited stock is -68.08%, while year-to-date (YTD) performance is -23.32%. ATHE stock has a five-year performance of -86.31%. Its 52-week range is between 2.53 and 8.73, which gives ATHE stock a 52-week price range ratio of 2.26%
Alterity Therapeutics Limited currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 0.55, a price-to-sale (PS) ratio of -14 892.20, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.28%, a ROC of -38.86% and a ROE of -38.97%. The company’s profit margin is -%, its EBITDA margin is 282 808.00%, and its revenue ttm is $-933.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Alterity Therapeutics Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Alterity Therapeutics Limited’s next earnings report date is -.
The consensus rating of Wall Street analysts for Alterity Therapeutics Limited is Moderate Buy (2), with a target price of $3, which is +12.36% compared to the current price. The earnings rating for Alterity Therapeutics Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alterity Therapeutics Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alterity Therapeutics Limited has a Neutral technical analysis rating based on Technical Indicators (ADX : 28.77, ATR14 : 0.26, CCI20 : -87.54, Chaikin Money Flow : -0.41, MACD : 0.05, Money Flow Index : 15.45, ROC : -19.09, RSI : 35.84, STOCH (14,3) : 16.87, STOCH RSI : 1.00, UO : 26.16, Williams %R : -83.13), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alterity Therapeutics Limited in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Moderate Buy|
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
CEO: David A. Stamler
Telephone: +61 393494906
Address: 460 Bourke Street, Melbourne 3000, VIC, AU
Number of employees: 12
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.